Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Bayer tests cerivastatin in renal disease

Bayer has announced the start of a two-year clinical trial to test whether early treatment with a statin can reduce cardiovascular morbidity and mortality in patients with end stage renal disease (ESRD). The principal investigator is Professor William Keane (University of Minnesota) who told a press briefing at the conference that, although lipid abnormalities were common in patients with chronic renal failure and ESRD, only around 8 per cent of haemodialysis patients in the United States currently received lipid lowering therapy. “To date, no statin outcome trials have been conducted in this patient population,” he said. Around 50 per cent of deaths in patients with ESRD were from cardiovascular disease. “It is the primary cause of death and we are doing nothing to decrease the cardiovascular disease burden in these patients.” 

The new trial is called CHORUS (cerivastatin in heart outcomes in renal disease: understanding survival). According to Bayer, the benefit of statins on ESRD outcomes might not only result from their lipid lowering properties. The company says that animal studies have shown that therapy can reduce proteinuria and glomerulosclerosis. The effect of the drugs on inflammatory processes that might contribute to cardiovascular disease will also be monitored. The trial will be carried out in Canada and the US. It will involve at least 1,000 patients new to haemodialysis who have “slightly elevated” lipid levels.

Citation: The Pharmaceutical Journal URI: 20002121

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.